linjc16/ctgov huggingface dataset:
The Role of Expectations in Experimentally Induced Sadness

Study Overview
=================
Brief Summary
-----------------
The study aimed at identifying whether different expectations have an impact on experiencing emotions in the form of sadness.

Official Title
-----------------
The Role of Expectations in Experimentally Induced Sadness

Conditions
-----------------
Healthy Participants

Intervention / Treatment
-----------------
* Other: Placebo nasal spray
* Other: Film Sequence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fluent in German language Exclusion Criteria: major depression current intake of psychotropic medication drug intake within the last two weeks alcohol consumption within the last twelve hours allergic to capsaicin allergic to sesame oil students in medicine, pharmacy, or psychology in their third year or older

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Positive placebo group<br>Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness. | Other: Placebo nasal spray<br> <br> Other: Film Sequence<br> <br> |
| Experimental: Negative placebo group<br>Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness. | Other: Placebo nasal spray<br> <br> Other: Film Sequence<br> <br> |
| Placebo Comparator: Placebo control group<br>Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness. | Other: Placebo nasal spray<br> <br> Other: Film Sequence<br> <br> |
| Other: No-treatment control group<br>Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness. | Other: Film Sequence<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sadness (PANAS-X) |  | Directly after watching the film sequence, no follow-up assessments |
Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function

Study Overview
=================
Brief Summary
-----------------
A pilot study of 15 subjects will be conducted to confirm an acute effect of grape seed extract on endothelial function. We then will perform a a randomized, double blind, placebo controlled crossover study designed to investigate the benefit of grape seed extract/vitamin C treatment on endothelial function. Participants (n=40) will take a food supplement containing 450 mg of grape seed extract and 1500 mg of vitamin C or matching placebo for four weeks and then cross over to the alternative treatment (active supplement or placebo) for four weeks. We will examine endothelial function before and after each of the two treatment periods. The study will provide information about the vascular effects of these compounds.

Official Title
-----------------
Chronic Study of the Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Grape seed extract and ascorbic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Coronary artery disease Exclusion Criteria: Pregnancy Clinical history of other major illness including end-stage cancer, renal failure, hepatic failure, gastrointestinal disorders that may impair absorption, or other conditions that in the opinion of the principal investigator make a clinical study inappropriate. Treatment with an investigational new drug within the last 30 days. History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study. Vitamin E, Vitamin C, and beta carotene, lipoic acid, and other food or herbal supplements within 1 month of enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brachial artery flow-mediated dilation |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fingertip Pulse Amplitude Tonometry |  | 1 month | 
| Carotid-femoral pulse wave velocity |  | 1 month | 
| Serum markers of inflammation |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endothelium, antioxidants, flavonoids
Indoor Air Quality and Infectious Aerosols in Health Care Facilities

Study Overview
=================
Brief Summary
-----------------
Outbreaks of emerging and re-remerging infectious diseases are frequently reported internationally in recent years, mainly due to global climate change, close human-livestock contact in developing countries, and globalization. Thus prevention, monitoring and control of infectious diseases are in urgent need to protect public health. High exposure risk to various infectious agents in health care facilities is of special concern, especially to airborne and droplet-borne respiratory diseases. To protect the health of public and health care workers the investigators will conduct a study to monitor indoor air quality and essential infectious aerosols in hospital(s). A questionnaire survey will be used to evaluate the relationships between employees' health and measured indoor environmental factors. The investigators will also examine whether the current indoor air quality recommendation of their country can reasonably reduce the risk of hospital infection. In addition, simple infectious aerosol indices will be established for future environmental management and monitoring in health care facilities.

Official Title
-----------------
Indoor Air Quality and Infectious Aerosols in Health Care Facilities

Conditions
-----------------
Indoor Air Quality, Infectious Aerosols

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: people who work in Health Care Facilities Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Indoor Air Quality, Infectious Aerosols
Exercise Adherence of Home-based Cardiac Rehabilitation

Study Overview
=================
Brief Summary
-----------------
The study explored the influencing factors of exercise adherence of home-based cardiac rehabilitation in patients with coronary artery disease.

Detailed Description
-----------------
The study used a qualitative exploratory design. Informants were recruited by purposive sampling. Semi-structured individual interviews were conducted among patients with coronary artery disease and medical professionals in home-based cardiac rehabilitation.

Official Title
-----------------
Qualitative Research on the Influencing Factors of Exercise Adherence of Home-based Cardiac Rehabilitation in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of coronary artery disease; Age ≤75 years old; Participated in home-based cardiac rehabilitation ≥12 weeks; Have good language skills; Volunteer to participate in this study. Exclusion Criteria: Have other serious acute or chronic diseases; A previous history of mental illness or a positive family history of mental illness; Have severe audio-visual or speech impairments that may affect understanding and answering questions.

Ages Eligible for Study
-----------------
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with coronary artery disease<br> | Other: interview<br>* semi-structured individual interview<br>|
| medical professionals<br> | Other: interview<br>* semi-structured individual interview<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influencing factors of exercise adherence | Influencing factors of exercise adherence in home-based cardiac rehabilitation | The influencing factors of exercise adherence in home-based cardiac rehabilitation will be measured by the construct of the theory of planned behavior through study completion, an average of 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease, Home-based cardiac rehabilitation, Exercise adherence
Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control. In this study, the protein where testosterone binds, called the androgen receptor (AR), will be measured in samples from the patient's biopsy and surgical tumor samples. The investigators will look at a marker of how fast the cancer is growing (Ki67) before using finasteride from your biopsy specimen. Finasteride will be taken from the day of consent until the day of the patient's surgery. This marker will be measured again after using finasteride from the surgical specimen. The investigators will be looking for a decrease in the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.

Official Title
-----------------
Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: finasteride 5mg oral daily


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male age >18 biopsy-proven non-small cell lung cancer surgical intervention planned Exclusion Criteria: current use of 5-alpha reductase inhibitor previous diagnosis of prostate cancer previous hypersensitivity to 5-alpha reductase inhibitor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: finasteride<br>finasteride 5mg po od from study entry to date of surgery | Drug: finasteride 5mg oral daily<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in proliferation | Patients will be followed from time of consent (around the time of consultation with a Thoracic Surgeon) to date of surgery (on average, approximately 4-6 weeks following Thoracic Surgeon consultation). | Original biopsy to surgical specimen (approx 6 weeks) |
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.

Official Title
-----------------
A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects

Conditions
-----------------
Hyperlipidemia, Hypertension

Intervention / Treatment
-----------------
* Drug: Livalo fixed combination drug
* Drug: Pitavastatin, Valsartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers Age 20-55 years at the time of Screening BMI 19-26 kg/m2 at the time of Screening Exclusion Criteria: Received other investigational drug within 90 days prior to the first dose of study drug

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Livalo fixed combination drug<br>Livalo fixed combination drug(Pitavastatin + Valsartan) | Drug: Livalo fixed combination drug<br>* Pitavastatin 4mg / Valsartan 160mg<br>|
| Active Comparator: Pitavastatin + Valsartan<br>Pitavastatin, Valsartan | Drug: Pitavastatin, Valsartan<br>* Pitavastatin 4mg, Valsartan 160mg<br>* Other names: Livalo, Diovan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax and AUC of study drugs after single oral administration |  | 0-48hrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of study drugs after single oral administration |  | 0-48hrs | 
| t1/2β of study drugs after single oral administration |  | 0-48hrs | 
| Tmax of study drugs after single oral administration |  | 0-48hrs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pitavastatin, Valsartan
An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection

Study Overview
=================
Brief Summary
-----------------
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.

Detailed Description
-----------------
Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.

Official Title
-----------------
An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection

Conditions
-----------------
Severe Acute Respiratory Syndrome Coronavirus 2

Intervention / Treatment
-----------------
* Biological: Mesenchymal stem cell


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SARS-CoV-2 infection is confirmed on antigen test or PCR test Pulmonary infiltrative shadow is confirmed on chest X-ray test Mechanical ventilation is being utilized, or Acute Respiratory Failure whose PaO2 is not being achieved to 80 mmHg in spite of High-flow oxygen therapy Exclusion Criteria: Continue treatment for Pneumonia before SARS-CoV-2 infection SOFA score >= 15 Infection type on DIC diagnosis criteria >= 4 Deep Venous Thrombosis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mesenchymal stem cell<br>4 times dose of Mesenchymal stem cell | Biological: Mesenchymal stem cell<br>* 1*10^8 cells are administered once a week, total four times intravenously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: Adverse Event | Adverse events which appear in subjects with ADR-001 treatment are evaluated. | 12 weeks |
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye

Study Overview
=================
Brief Summary
-----------------
Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.

Official Title
-----------------
Double-Masked, Randomized, Placebo-Controlled Study of Efficacy Parameter Following Administration of INS365 Ophthalmic Solution or Placebo in a Controlled Adverse Environment (CAE) Chamber in Subjects With Non-Sjogren's Associated Dry Eye

Conditions
-----------------
Keratoconjunctivitis Sicca

Intervention / Treatment
-----------------
* Drug: INS365 Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have Non-Sjogren's associated dry eye disease with symptoms lasting greater than 6 months had intermittent or regular artificial tear use within past 3 months Exclusion Criteria: had LASIK surgery had punctal occlusion or cauterization within last 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: INS365 Ophthalmic Solution|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Study Overview
=================
Brief Summary
-----------------
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Official Title
-----------------
A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: PF-03526299
* Drug: Placebo
* Drug: Fluticasone propionate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females 18-60 years Mild asthma Atopic to allergens Exclusion Criteria: Unstable asthma Smokers or recent ex-smokers Recent allergen challenge

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PF-03526299<br> | Drug: PF-03526299<br>* Inhaled, two doses 4 hours apart<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Inhaled, two doses 4 hours apart<br>|
| Active Comparator: Fluticasone propionate<br> | Drug: Fluticasone propionate<br>* Inhaled<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spirometry pre- and post- bronchial allergen challenge |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory safety tests |  | 2 months | 
| 12-lead ECGs |  | 2 months | 
| Adverse Event reporting |  | 2 months | 
| Blood samples for pharmacokinetic measurement |  | 2 months | 
| Sputum for pharmacodynamic measurement |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma Allergen Challenge